Clinical Trials

The Huntington Health Physicians Clinical Research program, established in 2004, was designed to compliment treatment options afforded to clients seeking quality medical care.

With the help of participants, we are able to discover ways to improve health, answer important scientific questions, and find new and improved ways to treat diseases. Clinical trials offer new approaches to diseases, new drug therapies, or combinations of therapies for a particular illness.

There is no cost to those who participate in clinical trials for 1) study medication, 2) study related testing, 3) clinical office visits related to research, 4) or physician assessments. A monetary stipend will be given to participants for each mandatory research visit to the clinic.

Below is a list of our current clinical trials. If you are interested in participating, please contact us at 626-204-1545 to see if you qualify.

Areas of research interest and prior experience in clinical trials:

  • Osteoporosis
  • GERD
  • Colitis
  • Diverticulitis
  • Rosacea
  • Psoriasis
  • Hypertension
  • Gout
  • Post MI
  • Rheumatoid Arthritis
  • Adult ADHD
  • Asthma
  • COPD
  • Diabetes
  • Lipid Lowering
  • Common Warts

Current Studies in Progress:

For more information contact Becky Lopez RN at 626-204-1545.

A Phase III 52 week study to evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects with Chronic Obstructive Pulmonary Disease

Primary Investigator: Chien Fang, MD

The purpose of this trial is to provide long-term safety data of once-daily TD-4208 over a dosing period of 52 weeks.

Eligibility for Enrollment:

  • Subject may be male or female and greater than or equal to 40 years of age who have a diagnosis of COPD. There will be spirometry testing to evaluate if the candidate is acceptable to enter the trial. All patients will get one of 2 doses of the TD-4208 or Spiriva. EKG, laboratory testing, physical exam will be performed free of charge.


Phase II 12 week study of the Safety and Tolerability of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation

Primary Investigator: Chien Fang, MD

The purpose of the study is to evaluate the efficacy and safety of Plecanatide for the treatment of IBS with constipation.

Eligibility for Enrollment:

  • 18-85 years of age
  • Diagnosis of Irritable bowel syndrome with constipation

Patients will receive study drug free, EKG, lab work, physical exam performed free of charge.


A Phase III clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared with the Addition of Dapagliflozin in Subjects with Type 2 Diabetes and Mild Renal Impairment Who have Inadequate Glycemic Control on Metformin

Primary Investigator: Chien Fang, MD

The purpose of the study is to evaluate the A1C after 24 weeks of treatment with addition of Sitagliptin or Dapagliflozin.

Eligibility for Enrollment:

  • Male or female at least 25 years of age
  • Diagnosis of Type 2 diabetes
  • Metformin therapy >/= 1500 mg/day
  • A1C greater than or equal to 7.0% and less than or equal to 9%
  • Have a BMI (Body Mass Index) greater than 18.0 kg/m2
  • Mild renal impairment (GFR between 60 and 90 ml/min/1.73m2

Patients will receive study drug free, EKG, lab work, physical exam performed free of charge.  Study participants will be responsible for their own doses of Metformin. There will be a total of 7 visits to the clinic.


Nano-Pulse efficacy for the Treatment of Common Warts

Primary Investigator: Stephani Takahashi, MD

A device that delivers low-energy, high voltage pulses to warts to effectively kill the wart virus. There are 4 possible application visits one month apart to the clinic and final evaluation at 3 months after the last treatment.  No cost to participant for study treatments or physician assessment.

Eligibility for Enrollment:

  • Male and female 18 years of age or older.
  • Common warts on body area that is accessible to treatment (no facial warts, genital warts or planter warts).


If you are interested in participating in any of our trials and would like more information, please call 626-204-1545.